Insilico Medicine lists on Hong Kong Stock Exchange, showing AI drug discovery momentum with 2025’s largest Hong Kong biotech IPO
Insilico Medicine raised a total of HKD 2.277 billion in its largest Hong Kong biotech IPO, with 94,690,500 shares offered globally and oversubscribed by approximately 1427 times. The company aims to advance its mission of extending human productive longevity using AI-powered drug discovery and development.